Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation ComparEd to StandaRd of Care Topical Cortico-Steroid Treatment In PatientS Who Undergo BilaTeral Pterygium Surgery PERSIST Study

Next Previous
Trial Profile

DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation ComparEd to StandaRd of Care Topical Cortico-Steroid Treatment In PatientS Who Undergo BilaTeral Pterygium Surgery PERSIST Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Antibacterials; Neomycin/polymixin B/dexamethasone; Prednisolone acetate
  • Indications Ocular inflammation; Ocular pain; Postoperative inflammation; Postoperative pain; Pterygium
  • Focus Therapeutic Use
  • Acronyms PERSIST

Most Recent Events

  • 25 May 2025 Status changed from active, no longer recruiting to completed.
  • 19 Jul 2022 Planned End Date changed from 1 May 2021 to 1 Jul 2022.
  • 19 Jul 2022 Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top